Brazilian isolates of Trypanosoma cruzi from humans and triatomines classified into two lineages using mini-exon and ribosomal RNA sequences

Traditional molecular and biochemical methods, such as schizodeme analysis, karyotyping, DNA fingerprinting, and enzyme electrophoretic profiles, have shown a large variability among Trypanosoma cruzi isolates. In contrast to those results, polymerase chain reaction (PCR) amplification of sequences from the 24Sα ribosomal RNA gene and from the mini-exon gene nontranscribed spacer indicated a dimorphism among T. cruzi isolates, which enabled the definition of two major parasite lineages. In the present study, 86 T. cruzi field stocks (68 isolated from humans with defined presentations of Chagas' disease and 18 from triatomines) derived from four Brazilian geographic areas were typed by the PCR assay based on the DNA sequences of the mini-exon and 24Sα rRNA genes. These stocks were ordered into the two major T. cruzi lineages. Lineage I was associated mainly with human isolates and lineage 2 with the sylvatic cycle of the parasite

The initiatives for the control of Chagas disease in the Americas and in non-endemic: overview and perspectives

Submitted by Leandro Borges ([email protected]) on 2020-01-09T13:44:22Z No. of bitstreams: 1 Coura_et_al_IOC_2009.pdf: 6535958 bytes, checksum: 7a277624b5e893699470ab50f76eb34c (MD5)Approved for entry into archive by Leandro Borges ([email protected]) on 2020-01-09T14:14:33Z (GMT) No. of bitstreams: 1 Coura_et_al_IOC_2009.pdf: 6535958 bytes, checksum: 7a277624b5e893699470ab50f76eb34c (MD5)Made available in DSpace on 2020-01-09T14:14:33Z (GMT). No. of bitstreams: 1 Coura_et_al_IOC_2009.pdf: 6535958 bytes, checksum: 7a277624b5e893699470ab50f76eb34c (MD5) Previous issue date: 2009Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Manaus, AM, Brasil.Organização Mundial da Saúde. Washington, DC, EUA.Fundação Oswaldo Cruz. Centro de Pesquisa René Rachou. Belo Horizonte, MG, Brasil.Organização Pan Americana da Saúde. Brasília, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Banco Inter-Americano de Desarollo. Programa Regional para el Control de la Enfermedad de Chagas en America Latina. Montevideo, Uruguay.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Centro de Pesquisa René Rachou. Belo Horizonte, MG, Brasil.Organização Mundial da Saúde. Washington, DC, Estados Unidos.As iniciativas multinacionais para o controle da doença de Chagas existem nos países do Cone Sul, nos países Andinos, na América Central e México, na Região Amazônica e nos Países Não-Endêmicos. Estes esforços internacionais permitiram enormes avanços na prevenção da transmissão vetorial e transfusional da doença de Chagas. Contudo, quedam grandes desafios pela frente, incluindo: (I) o estímulo ou re-estabelecimento da prioridade política para a doença de Chagas; (II) o reforço da coordenação internacional e da avaliação dos programas nacionais através das iniciativas; e (III) a definição e implementação efetiva dos padrões de qualidade para todas as ações preventivas. Deve se conceder prioridade ao controle vetorial e ao cuidado dos pacientes, incluindo o tratamento específico de casos agudos e dos pacientes crônicos de até 15 anos de idade.Multinational iniciatives for the control os Chagas disease exist in the Southern Cone Countries, the Andean Countries, Central America and Mexico, the Amazon Region, and the Non-Endemic Countries. These international efforts allowed for huge advances in the prevention of vectorborne and transfusion-related Chagas disease transmission. However, major challenges lie ahead, including: (I) to foster or re-estabilish political priority for Chagas disease; (II) to enhance international co-ordination and evaluation of national programs through the initiatives; and (III) to define and enforce quality standards for all preventive actions. Priority must be given to vector control and patient care, including specific treatment for acute and chronic patients up to 15 years old

Two main clusters within Trypanosoma cruzi zymodeme 3 are defined by distinct regions of the ribosomal RNA cistron

Trypanosoma cruzi is currently classified into 2 major phylogenetic lineages, T. cruzi I and II, that correlate with the formerly described zymodeme 1 and 2, respectively. Another isoenzymic group (zymodeme 3-Z3) was also described. In this study, we analysed the genetic diversity among Z3 isolates of the Brazilian Amazon by restriction fragment length polymorphism of the intergenic transcribed spacers (ITSs) of the ribosomal RNA cistron and the size of the divergent domain D7 of the 24Sα rRNA gene. DNAs from 12 T. cruzi Z3 isolates obtained from humans (2), Panstrongylus geniculatus (1), and Rhodnius brethesi (9) were submitted to PCR amplification of the ITSs plus the 5.8S rDNA. The PCR products were digested with 4 distinct endonucleases and the profiles analysed by a numerical methodology. The phenetic dendrogram revealed a clear dichotomy in the Z3 group, defining 2 groups that were named Z3-A and Z3-B. Dimorphism was also found in the band sizes of the amplified D7 divergent domain of the 24Sα rDNA, which showed a perfect correlation with the ITSs clustering. The organization of the ribosomal cistron was investigated by Southern blotting and shown to be conserved in the genome of the 2 Z3 groups. This study shows that the rDNA cistron allows the definition of 2 distinct subclusters in Z3 isolates

Technical recommendation on Chagas' Disease epidemiology and prevention, focussing its transmission as a disease transmitted by food

Organización Panamericana de la Salud/Organización Mundial de la Salud. HDM/VP. Brasilia, DF, Brasil.Organización Panamericana de la Salud/Organización Mundial de la Salud. PFR em Doença de Chagas. Montevidéu, Uruguai.Organización Panamericana de la Salud/Organización Mundial de la Salud. HDM/VP. Brasilia, DF, Brasil.Universidade Federal do Triângulo Mineiro. Uberaba, MG, Brasil.Agência Nacional de Vigilância Sanitária. Brasilia, DF, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Agência Nacional de Vigilância Sanitária. Brasilia, DF, Brasil.Sem Afiliação.Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Rio de Janeiro, RJ, Brasil.Secretaria de Estado de Saúde. Diretoria de Vigilância Sanitária. Florianópolis, SC, Brasil.Agência Nacional de Vigilância Sanitária. Brasilia, DF, Brasil.Ministerio da Salud. Lima, Perú.Fundação Oswaldo Cruz. Instituto René Rachou. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Agência Nacional de Vigilância Sanitária. Brasilia, DF, Brasil.Ministerio de Salud. Quito, Ecuador.Universidade de São Paulo. Faculdade de Medicina. São Paulo, SP, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Agência Nacional de Vigilância Sanitária. Brasilia, DF, Brasil.Agência Nacional de Vigilância Sanitária. Brasilia, DF, Brasil.Instituto Nacional de Salud. Bogotá, Colômbia.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Ananindeua, PA, Brasil.Agência Nacional de Vigilância Sanitária. Brasilia, DF, Brasil.Fundação Oswaldo Cruz. Instituto Gonzalo Moniz. Rio de Janeiro, RJ, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Brasília, DF, Brasil